BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Accenture
Express Scripts
Cipla
Cantor Fitzgerald
Deloitte
Dow
McKinsey
QuintilesIMS
Teva

Generated: January 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,906,542

« Back to Dashboard

Which drugs does patent 7,906,542 protect, and when does it expire?

Patent 7,906,542 protects XIFAXAN and is included in two NDAs.

This patent has eighty-one patent family members in thirty-five countries.
Summary for Patent: 7,906,542
Title:Pharmaceutical compositions comprising polymorphic forms .alpha., .beta., and .gamma. of rifaximin
Abstract:Crystalline polymorphous forms of rifaximin (INN), referred to as rifaximin .alpha. and rifaximin .beta., and a poorly crystalline form referred to as rifaximin .gamma., useful in the production of medicaments containing rifaximin for oral and topical use and obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a fixed temperature and for a fixed period of time, followed by a drying under controlled conditions until reaching a precise water content in the end product, are the object of the invention.
Inventor(s): Viscomi; Giuseppe Claudio (Bologna, IT), Campana; Manuela (Bologna, IT), Braga; Dario (Bologna, IT), Confortini; Donatella (Bologna, IT), Cannata; Vincenzo (Bologna, IT), Righi; Paolo (Bologna, IT), Rosini; Goffredo (Bologna, IT)
Assignee: Alfa Wassermann, S.p.A. (Bologna, IT)
Application Number:12/119,622
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Formulation;

Drugs Protected by US Patent 7,906,542

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Salix Pharms XIFAXAN rifaximin TABLET;ORAL 021361-001 May 25, 2004 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Salix Pharms XIFAXAN rifaximin TABLET;ORAL 022554-001 Mar 24, 2010 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,906,542

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,835,452 Polymorphic forms .alpha., .beta. and .gamma. of rifaximin ➤ Subscribe
7,045,620 Polymorphous forms of rifaximin, processes for their production and use thereof in medicinal preparations ➤ Subscribe
8,158,781 Polymorphic forms .alpha., .beta. and .gamma. of rifaximin ➤ Subscribe
7,923,553 Processes for the production of polymorphic forms of rifaximin ➤ Subscribe
8,404,704 Use of polymorphic forms of rifaximin for medical preparations ➤ Subscribe
8,158,644 Pharmaceutical compositions comprising polymorphic forms .alpha., .beta., and .gamma. of rifaximin ➤ Subscribe
7,612,199 Polymorphic forms .alpha., .beta., and .gamma. of rifaximin ➤ Subscribe
7,902,206 Polymorphic forms .alpha., .beta. and .gamma. of rifaximin ➤ Subscribe
7,915,275 Use of polymorphic forms of rifaximin for medical preparations ➤ Subscribe
8,853,231 Pharmaceutical compositions comprising polymorphic forms .alpha., .beta., and .gamma. of rifaximin ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,906,542

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 043547 ➤ Subscribe
Argentina 081991 ➤ Subscribe
Argentina 081992 ➤ Subscribe
Austria 361927 ➤ Subscribe
Austria 421965 ➤ Subscribe
Austria 421966 ➤ Subscribe
Australia 2004200964 ➤ Subscribe
Australia 2004287601 ➤ Subscribe
Brazil PI0402382 ➤ Subscribe
Brazil PI0407149 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
QuintilesIMS
McKesson
Citi
Colorcon
Cipla
Fish and Richardson
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot